Innovative implant reduces cancer recurrence after surgery for soft tissue sarcomas
Supratherapeutic PTX Buttresses Reduce Locoregional Recurrence Rates Following Surgery for Soft Tissue Sarcomas
['FUNDING_R01'] · BRIGHAM AND WOMEN'S HOSPITAL · NIH-10914027
This study is looking at a new way to help prevent soft tissue sarcomas from coming back after surgery by using a special implant that slowly releases a chemotherapy drug right where the tumor was removed, making it a friendly option for patients who have had this type of cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BRIGHAM AND WOMEN'S HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10914027 on ClinicalTrials.gov |
What this research studies
This research investigates a new surgical approach to prevent locoregional recurrence of soft tissue sarcomas after surgery. It involves the use of a specially designed implant that delivers high concentrations of a chemotherapy drug directly to the surgical site. The implant is made from a blend of polymers that allows for sustained release of the drug, aiming to improve outcomes for patients who have undergone surgery for these tumors. By targeting the area where the tumor was removed, the research seeks to reduce the chances of cancer returning in the same location.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who have been diagnosed with soft tissue sarcomas and are scheduled for surgical resection.
Not a fit: Patients with distant metastases or those who are not candidates for surgical intervention may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly lower the rates of cancer recurrence in patients who have had surgery for soft tissue sarcomas.
How similar studies have performed: While similar approaches have been explored, this specific method of using a high-dose chemotherapeutic implant is novel and has not been extensively tested in prior studies.
Where this research is happening
BOSTON, UNITED STATES
- BRIGHAM AND WOMEN'S HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RAUT, CHANDRAJIT PREMANAND — BRIGHAM AND WOMEN'S HOSPITAL
- Study coordinator: RAUT, CHANDRAJIT PREMANAND
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents